Pretomanid Tablets Market
Author : Pratik Gohel | Published On : 06 Nov 2026
Global Pretomanid Tablets Market Forecast Through 2034
Market analysis projects a value of USD 377.0 million by 2034, with demand, product segmentation and regional developments shaping the outlook.
The global pretomanid tablets market was valued at USD 164.0 million in 2025 and is estimated at USD 179.9 million in 2026. According to Intel Market Research, the market is forecast to reach USD 377.0 million by 2034, registering a compound annual growth rate of 9.7% during 2026–2034. The study examines market demand, product categories, application channels, regional trends and participating organizations. The forecast reflects the combined influence of clinical or consumer requirements, product availability, distribution and changes in the competitive environment.
Read the full market report: View Report
Market Overview
Pretomanid is a nitroimidazole medicine supplied as a 200 mg oral tablet and used in combination with bedaquiline and linezolid, with moxifloxacin where clinically appropriate. WHO guidance prioritizes a six-month combination regimen for eligible patients with drug-resistant tuberculosis. Treatment requires susceptibility testing, clinical monitoring and assessment of patient suitability. The commercial unit in this report is the pretomanid tablet supplied to public programmes, wholesalers and hospitals, not companion antibiotics or diagnostic services.
Key Findings
· Market revenue is projected to increase from USD 164.0 million in 2025 to USD 377.0 million by 2034.
· The 2026 market estimate is USD 179.9 million, with a 9.7% CAGR forecast for 2026–2034.
· Asia, 54% is identified as the leading regional market.
· The report examines the market through product, application, channel or end-user segments relevant to this category.
· Product availability, regulatory or clinical requirements, distribution and competition are important factors shaping the outlook.
Request a sample and review report details: Download / Request Sample
Growth Drivers
Demand is tied to treatment programmes for rifampicin-resistant and multidrug-resistant tuberculosis rather than routine retail prescribing. The report notes the continuing global treatment gap and the use of shorter combination regimens for eligible patients. WHO treatment guidance and prequalification of products from multiple suppliers support procurement and programme access. Public-health purchasing, country-level treatment budgets and the availability of qualified products are important factors influencing growth.
Challenges
The market depends on public procurement, international quality qualification and country-level treatment budgets. Pretomanid is used as part of a combination regimen, so demand follows eligible patient numbers and treatment-programme planning. Susceptibility testing, clinical monitoring and patient eligibility requirements influence use. Manufacturers must maintain reliable supply and meet regulatory and prequalification requirements.
Market Segmentation
Pack types: 26 tablets per box and 182 tablets per bottle. Packaging: bottle and box. Production technology: innovator and generic. Applications: multidrug-resistant tuberculosis, extensively drug-resistant tuberculosis and others.
Regional Analysis
Asia is the largest regional market, with an estimated 54% share of 2025 revenue. The region includes important generic suppliers and public-health procurement activity. The report notes WHO prequalification records for products associated with Mylan, Macleods and Lupin. Regional demand is influenced by treatment programme coverage, budgets and product qualification.
Competitive Landscape
The competitive field depends on international quality qualification, public procurement and licensing architecture. Mylan Laboratories (Viatris) is identified in originator-linked supply, while Macleods and Lupin also have WHO-prequalified pretomanid tablet products. Suppliers compete through regulatory documentation, continuity of qualified supply and pack formats suited to treatment courses.
Market Outlook
The forecast period provides a consistent basis for reviewing how the market may develop from its 2025 base year through the 2034 outlook. The 2026 estimate offers an intermediate reference point, while the stated CAGR summarizes the expected pace of revenue change over 2026–2034. These indicators should be considered together with the report's product scope, regional coverage and market segmentation.
Why the Report Matters
The report provides market sizing and forecasts for a specialized medicine used in drug-resistant tuberculosis programmes. Its segmentation by pack format, packaging, production technology and application helps readers understand how public procurement shapes demand. It distinguishes pretomanid tablet value from the broader combination regimen and associated diagnostics.
Explore the complete report for detailed forecasts, segmentation and company analysis: Intel Market Research Report
About Intel Market Research: Intel Market Research provides market intelligence and strategic research across industry sectors. For report information, sample requests or other enquiries, contact [email protected] or call +91 9169164321.
Sample request: Request a Free Sample
